WO2025041102 - TARGETED IMMUNE ACTIVATION WITH IL-18 IMMUNOCYTOKINES
National phase entry is expected:
Publication Number
WO/2025/041102
Publication Date
27.02.2025
International Application No.
PCT/IB2024/058236
International Filing Date
23.08.2024
Title **
[English]
TARGETED IMMUNE ACTIVATION WITH IL-18 IMMUNOCYTOKINES
[French]
ACTIVATION IMMUNITAIRE CIBLÉE AVEC DES IMMUNOCYTOKINES IL-18
Applicants **
BRIGHT PEAK THERAPEUTICS AG
Inventors
KREFT, Bertolt
PATTABIRAMAN, Vijaya Raghavan
CARRALOT, Jean-Philippe
MARTIN, Kea
GOEPFERT, Arnaud
Priority Data
63/534,298
23.08.2023
US
63/535,496
30.08.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5512 | |
| EPO | Filing, Examination, Granting | 65457 | |
| Japan | Filing, Examination, Granting | 4091 | |
| South Korea | Filing, Examination, Granting | 5711 | |
| USA | Filing, Examination, Granting | 18140 |
Total:
98,911
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to modified immunocytokine compositions comprising antibodies or antigen binding fragments specific for immune cell antigens (e.g., PD-1) and IL-18 polypeptides which are able to selectively stimulate the immune system at desired locations, such as within a tumor microenvironment. Such immunocytokines are in some instances useful for the expansion of CD8+ T cells in a subject, preferably in a tumor or tumor microenvironment of the subject. Also provided herein are methods of treatment with and methods of manufacture of immunocytokine compositions.[French]
La présente divulgation concerne des compositions d'immunocytokines modifiées comprenant des anticorps ou des fragments de liaison à l'antigène spécifiques d'antigènes de cellules immunitaires (par exemple, PD-1) et des polypeptides IL-18 pouvant stimuler sélectivement le système immunitaire à des emplacements souhaités, tels que dans un microenvironnement tumoral. De telles immunocytokines sont dans certains cas utiles pour l'expansion de lymphocytes T CD8+ chez un sujet, de préférence dans un microenvironnement tumoral ou tumoral du sujet. La divulgation concerne également des méthodes de traitement et des méthodes de fabrication de compositions d'immunocytokine.